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DOI 10.1016/j.ccr.2011.05.025SUMMARYClinical and genomic evidence suggests that the metastatic potential of a primary tumor may be dictated by
prometastatic events that have additional oncogenic capability. To test this ‘‘deterministic’’ hypothesis, we
adopted a comparative oncogenomics-guided function-based strategy involving: (1) comparison of global
transcriptomes of two genetically engineered mouse models with contrasting metastatic potential, (2)
genomic and transcriptomic profiles of human melanoma, (3) functional genetic screen for enhancers of
cell invasion, and (4) evidence of expression selection in human melanoma tissues. This integrated effort
identified six genes that are potently proinvasive and oncogenic. Furthermore, we show that one such
gene, ACP5, confers spontaneous metastasis in vivo, engages a key pathway governing metastasis, and
is prognostic in human primary melanomas.INTRODUCTION
Cancers are highly heterogeneous on both the genomic and
cellular levels such that similarly staged early disease can exhibit
radically different clinical outcomes—from cure following
surgical removal of the primary tumor to death within months
of diagnosis due to widespread metastasis. Metastasis isSignificance
Early-stage melanoma is often cured by surgical excision, yet
with lethal metastatic disease despite successful surgical rem
underlying such aggressive biology has been a long-standing f
rational therapeutics for high-risk patients diagnosed with earl
vant setting. This study illustrates how one can exploit and inte
cancer genomics knowledge, and functional screens to identif
fide oncogenes.
92 Cancer Cell 20, 92–103, July 12, 2011 ª2011 Elsevier Inc.responsible for the majority of cancer-related mortality and
involves multiple interrelated steps by which primary tumor cells
spread to establish cancerous lesions at distant sites (Gupta and
Massague, 2006). To become metastatic, tumor cells acquire
a number of biological capabilities to overcome barriers of
dissemination and distant growth such as invasion, anoikis
resistance, extravasation, colonization, and growth in newsome cases without clinical evidence of dissemination recur
oval of the primary tumor. Elucidation of the molecular basis
ocus, with the goal of identifying prognostic biomarkers and
y-stage disease who are in need of further treatment in adju-
grate genetically engineered mouse models, cross-species
y robust proinvasion drivers of metastasis that are also bona
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conferred by genetic or epigenetic events observed in tumors
(Hanahan and Weinberg, 2011), supporting the thesis that
biological heterogeneity of cancers, including metastatic
potential, is dictated by underlying genomic alterations.
Although significant data exist in support of a classical model
of stepwise accumulation of genetic events that endow
increasing malignant potential, the identification of extensive
genome rearrangements in early-stage cancers (driven in part
by telomere crisis) (Rudolph et al., 2001; Chin et al., 2004)
raises the possibility that some tumors may acquire genomic
alterations with significant metastatic potential early in their
evolution. Such tumors would inherently carry higher risk for
metastasis despite early diagnoses. This deterministic model is
consistent with the finding that transcriptomic profiles of primary
tumors share striking resemblance with their metastatic lesions
(Perou et al., 2000), and gene expression patterns of the primary
bulk tumor can predict the likelihood of recurrence or metastatic
spread, e.g., MammaPrint and OncotypeDx (van‘t Veer et al.,
2002; Paik et al., 2004). Furthermore, the prognostic significance
of these gene expression signatures supports the view that
information on metastatic propensity is encoded in the bulk of
the primary tumor (van ‘t Veer et al., 2002; van de Vijver et al.,
2002; Ramaswamy et al., 2003).
Together, these observations lead one to posit that prometa-
static genetic alterations acquired early at primary tumor stage
might themselves be classical oncogenes and tumor suppressor
genes that can confer a selective growth advantage during
tumorigenesis, and if so, such genes would be subject to recur-
rent genomic alterations in cancer (i.e., amplification and loss).
Therefore, the existence and identification of such prometastasis
oncogenes could provide both prognostic markers as well
as therapeutic targets for inherently aggressive early-stage
cancers. In this study, usingmelanoma as a diseasemodel given
its cardinal feature of high metastatic propensity, we sought to
validate the concept of ‘‘oncogenic driver of metastasis’’ or
‘‘metastasis oncogenes’’ through systematic identification of
putative metastasis driving genes that also confer transforming
oncogenic activity in early-stage cancers.
RESULTS
Evolutionarily Conserved, Differentially Expressed
Genes with Metastatic Potential
The enormous genomic complexity of humanmelanoma and the
less than complete certainty surrounding occult metastatic
disease in any given human patient prompted us to compare
two extensively characterized genetically engineered mouse
(GEM) models of human melanoma with distinct metastatic
profiles. The selected melanoma models are: (1) the
HRASV12G-driven mouse melanoma model (Tyr-rtTA;Tet-
HRASV12G;INK4A/ARF/, hereafter ‘‘iHRAS*’’), which develops
aggressive cutaneous melanomas that do not metastasize
(Chin et al., 1997, 1999); and (2) a MET-driven GEM model
(Tyr-rtTA;Tet-Met;INK4A/ARF/, hereafter ‘‘iMet’’), which
develops metastatic melanomas. The iMet model expresses an
inducible c-MET transgene (Tet-Met) and is constructed
following a similar engineering strategy used for the iHRAS*
model (Ganss et al., 1994; Chin et al., 1997, 1999) (see Supple-mental Experimental Procedures available online). Tet-Met
transgenic animals were bred with transgenic mice carrying
the reverse tetracycline transactivator under the control of tyros-
inase gene promoter-enhancer elements (designated Tyr-rtTA)
(Gossen et al., 1995). Given the frequency and demonstrated
relevance of INK4A/ARF deletions in melanoma (Hussussian
et al., 1994; Kamb et al., 1994), these compound transgenic
alleles were further intercrossed onto an INK4A/ARF null back-
ground to generate cohorts of single- and double-transgenic
mice (designated iMet) deficient for INK4A/ARF whose melano-
cytes expressMET upon induction with doxycycline (Figure 1A).
iMet mice develop melanomas at sites of skin wounding
with an average latency of 12 weeks (Table S1). These lesions
are positive for prototypical melanocyte markers and express
phospho-Met (c-Met) receptor and its ligand hepatocyte growth
factor (HGF) (Figures 1B and 1C; Figures S1A and S1B). These
iMet melanomas uniformly metastasize to lymph nodes and
show occasional dissemination to the adrenal glands and lung
parenchyma, which are common sites for metastases in human
melanoma (Figure 1D). In sharp contrast the iHRAS* melanoma
model develops aggressive cutaneous melanomas that do not
metastasize (Chin et al., 1997, 1999). Consistent with the con-
trasting metastatic potential of iMet and iHRAS* primary tumors,
only iMet melanoma-derived cell lines were able to seed and
grow to large macroscopic lesions in tail vein experimental
metastasis assays (Figure S1C).
Using these two GEM models as ‘‘extreme cases,’’ we
compared the transcriptomic profiles of primary cutaneous
melanomas from iHRAS* and iMet models to define 1597 gene
probe sets with R2-fold differential expression at a false
discovery rate <0.05. This list of differentially expressed genes
was next intersected with genes residing in recurrent copy
number aberrations (CNAs) in human metastatic melanoma
(GEO accession #GSE7606) and/or genes exhibiting significant
differential expression between primary and metastatic mela-
nomas in human (Kabbarah et al., 2010). This comparative
oncogenomics analysis led to a list of 360 genes comprised of
295 upregulated/amplified and 65 downregulated/deleted
candidates (Figure 2A; Table S2), representing differentially ex-
pressed genes in primary melanoma that are correlated with
metastatic potential. Compared with the 1597 probe set, this
cross-species intersected list of 360 genes was significantly
more enriched for cancer-relevant functional networks based
on Ingenuity Pathway Analysis (IPA) (Figure S2A).
Identification of Proinvasion Oncogenes
From the aforementioned cross-species triangulated gene list for
metastatic potential, we set out to identify functionally active
metastasis drivers in primary melanomas following the experi-
mental outline in Figure 2B. In particular we designed a genetic
screen for invasion based on the rationale that the ability of
primary melanoma cells to invade downward into the dermis
and subcutis is significantly correlated with metastasis, and
a primary melanoma with proinvasive genetic events is more
likely to metastasize early; hence, we postulated that metastasis
drivers in such primary melanoma would harbor proinvasive
activity. Here, we elected to focus on the 295 upregulated
genes using a gain-of-function screening design given their
possible therapeutic potential. The human ORFeome collectionCancer Cell 20, 92–103, July 12, 2011 ª2011 Elsevier Inc. 93
Figure 1. Melanocyte-SpecificMETExpres-
sion Promotes Formation of Cutaneous
Metastatic Melanoma
(A) Melanocytes were harvested from the indi-
cated animals (INK4A/ARF/, Tet-Met, and iMet)
and adapted to culture for total RNA extraction
following treatment with or without doxycycline
(Dox). Expression of MET (Tg MET) was assayed
by RT-PCR using transgene-specific primers.
R15, ribosomal protein R15 internal control; -RT,
no reverse transcriptase PCR control.
(B) qRT-PCR was performed to analyze HGF
expression in MET-induced primary melanomas
(T1–T6). Tumor expression data are normalized to
expression in two INK4A/ARF/ melanocyte cell
lines. Error bars indicate ± SD.
(C) Immunohistochemical staining of total Met
(c-Met) and phosphorylated (Phospho) c-Met in
a MET-induced primary melanoma. The arrow
points to a follicle (f). Scale bars, 100 mm (left) and
50 mm (right).
(D) H&E sections of a primary cutaneous spindle
cell melanoma in the dorsal skin of an iMet trans-
genic mouse induced with doxycycline and distal
metastases residing in lymph node, adrenal gland,
and lung. Scale bars, 50 mm (primary tumor [t]) and
100 mm (metastases).
See also Figure S1 and Table S1.
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Oncogenic Metastasis Drivers in Melanomac-met (http://horfdb.dfci.harvard.edu/) contained 230 open
reading frame (ORF) cDNAs corresponding to 199 of the 295
unique upregulated/amplified candidates (Table S3), which
were then transferred to a lentiviral expression system for trans-
duction into HMEL468 (PMEL/hTERT/CDK4(R24C)/p53DD),
a TERT-immortalized primary humanmelanocyte line engineered
to express BRAFV600E (Garraway et al., 2005). For the primary
screen we utilized a 96-well transwell invasion assay with fluoro-
metric readout to measure the ability of candidate genes to
enhance migration and invasion of HMEL468 through Matrigel,
which simulates extracellular matrix. Lentiviral expression
vectors encoding GFP and NEDD9 (Kim et al., 2006; O’Neill
et al., 2007; Sanz-Moreno et al., 2008; Izumchenko et al., 2009)
were used as negative and positive controls, respectively. The
primary screen was performed in duplicate, and 45 candidates
that reproducibly scored two standard deviations from the GFP
control were considered as primary screen hits (Figure S2B and
Table S3). Secondary validation of these 45 candidate genes94 Cancer Cell 20, 92–103, July 12, 2011 ª2011 Elsevier Inc.was performed by assaying their invasive
ability in standard 24-well Matrigel inva-
sion chambers, together with parallel
sequencing and expression verification
(see Supplemental Experimental Proce-
dures), yielding 18 genes (Table S4) pos-
sessing >2-fold enhancement of invasion
compared to the GFP control (Figure 2C
and Table 1). As a frame of reference,
the positive control prometastasis gene
NEDD9, which has been shown to be
required for cell movement (Sanz-Moreno
et al., 2008) and in vivo metastasis ofbreast cancers (Izumchenko et al., 2009), enhanced invasion by
1.5-fold in this system (data not shown).
To prioritize downstream validation efforts, we next assayed
the 18 candidates for ability to confer a 2-fold increase of inva-
sion in a second melanoma cell system, WM115. This identified
11 robust proinvasion genes (Table 1). Mindful of the artificial
nature of in vitro invasion screen and limitation of an overexpres-
sion system, we then interrogated the expression patterns of
these proinvasion genes in human melanocytic lesions for
evidence of human relevance, specifically increasing expression
from benign to malignant and/or from primary to metastasis
lesions as criteria for clinicopathological validation. To this end,
we rigorously screened commercially available antibodies and
successfully qualified and optimized conditions of 7 antibodies
for proteins encoded by 7 of the 11 genes for quantitative immu-
nofluorescence staining on formalin-fixed paraffin-embedded
tissue. Using the Automated Quantitative Analysis (AQUA)
platform (Camp et al., 2002), we quantitated protein expression
Figure 2. Multidimensional Genomic Anal-
yses and Low-Complexity Functional
Genetic Screen for Cell Invasion
(A) Schematic illustrating the integrative cross-
species oncogenomics comparison.
(B) Flowchart depicting the low-complexity
genetic screen for invasion and validation
processes.
(C) Histogram of 18 proinvasion genes satisfying
sequencing, expression, and secondary screen
verification efforts. Representative invasion
chamber images for HMEL468 cells stably
expressing HOXA1 and ACP5 are shown. GFP,
negative control; TNTC, too numerous to count.
Scale bar, 1.6 mm.
See also Figure S2 and Tables S2–S4.
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(YTMA98) containing 20 specimens each of benign nevi, primary
melanoma, andmelanomametastases. As summarized inTable 1,
proteins encoded by six of seven (ACP5, FSCN1,HOXA1,HSF1,
NDC80, VSIG4) proinvasion genes showed significantly higher
expression across the benign-to-malignant and/or primary-to-
metastasis transitions in human (Table 1; Figure S3), qualifying
them as validated proinvasion genes in human melanomas.
The acquisition of metastasis drivers in some early-stage
tumors might reflect their roles as bona fide oncogenes that
could provide a proliferative advantage to the emergent primary
tumors as speculated by Bernards and Weinberg (2002). To test
this hypothesis, we examined the oncogenic potential of the six
validated proinvasion genes by assaying their requirement in
maintaining the tumorigenic phenotype of established human
melanoma cells in vitro and their ability to transform immortalized
humanmelanocytes in vivo. For example, using anchorage-inde-
pendent growth as a surrogate for tumorigenic phenotype,
depletion of ACP5 using two independent shRNAs in the human
melanoma cell line 1205Lu resulted in a 56% reduction in soft-Cancer Cell 20, 92agar colony formation (p = 0.0001) (Fig-
ure 3A). Conversely, HMEL468 melano-
cytes (1 3 106 cells/injection) stably
expressing ACP5 became robustly
tumorigenic when subcutaneously im-
planted into the right flank of athymic
nude mice (p = 0.0012) (Figure 3B).
Importantly, extending these assays to
the remaining five proinvasion genes,
we found that knockdown of all six in
M619 and C918 human melanoma cells
significantly decreased colony formation
when compared with nontargeting
(shGFP) shRNA (Figure 3C; Figure S4).
Similarly, mice injected with HMEL468
cells overexpressing each of the six
genes developed tumors, compared to
none of the animals injected with GFP
control HMEL468 cells after 30 weeks of
observation (Figure 3D). Together, these
complementary loss- and gain-of-func-
tion studies demonstrated unequivocallythat all six of these proinvasion genes are oncogenic. These
results are striking given that transforming activity of these genes
was not screened for in the course of their identification.
In summary, from the initial cross-species differentially ex-
pressed list of 199 genes enlisted into the functional screen for
cell invasion, 18 candidate metastasis oncogenes were identi-
fied. Of these, seven candidates were prioritized for multilevel
functional and clinicopathological validation; six were confirmed
as potent proinvasion oncogenes, capable of robust transform-
ing and invasive activities in immortalized nontransformed
human melanocytes and whose expressions positively corre-
lated with human melanoma transformation or progression.
Functional and Clinical Validation of ACP5
Our integrated functional genomics screen and validation above
have identified six proinvasion oncogenes that are posited to
confer enhanced metastasis risk in vivo and, therefore, carry
prognostic significance in patients diagnosed with primary mela-
nomas. To seek evidence in support of this, we next focused on
ACP5 as a proof-of-concept example based on the observations–103, July 12, 2011 ª2011 Elsevier Inc. 95
Table 1. Invasion Validation and Progression-Correlated Expression Analysis
Metastasis
Oncogene
Candidates Gene ID Gene Name
HMEL468
Invasion
Screen
Invasion
Activity
in WM115
Clinicopathological Validationa
Oncogenic
In VivoTransformationb Progressionc Passed?
ACP5 54 Acid phosphatase 5,
tartrate resistant
6.5X 2.1X p = 0.001 p = 0.026 Yes Yes
FSCN1 6624 Fascin homolog 1,
actin-bundling protein
2.4X 2.2X ns p = 0.026 Yes Yes
HOXA1 3198 Homeobox A1 TNTC 6.1X p < 0.001 ns Yes Yes
HSF1 3297 Heat shock transcription
factor 1
2.8X 4.4X p = 0.003 ns Yes Yes
NDC80 10403 ndc80 homolog,
kinetochore component
2.4X 2.2X ns p = 0.034 Yes Yes
VSIG4 11326 V set and immunoglobulin
domain cont. 4
4.8X 2.1X p < 0.001 ns Yes Yes
NCAPH 23397 Non-SMC condensin
I complex, subunit H
3.5X 2.1X ns ns No nt
ASF1B 55723 ASF1 anti-silencing
function 1 homolog B
4.7X 2.0X No antibody nf
MTHFD2 10797 Methylenetetrahydrofolate
dehydrogenase
2.4X 2.5X No antibody nf
RNF2 6045 Ring finger protein 2 2.9X 3.4X No antibody nf
SPAG5 10615 Sperm associated
antigen 5
3.2X 2.5X No antibody nf
ANLN 54443 Anillin, actin binding
protein
2.6X ns
DEPDC1 55635 DEP domain containing 1 2.3X ns
HMGB1 3146 High-mobility group box 1 3.4X ns
ITGB3BP 23421 Integrin beta 3 binding
protein
4.2X ns
MCM7 4176 Minichromosome
maintenance complex 7
9.4X ns
UBE2C 11065 Ubiquitin-conjugating
enzyme E2C
3.9X ns
UCHL5 51377 Ubiquitin carboxyl-terminal
hydrolase L5
4.1X ns
nt, not tested; ns, not significant; nf, not followed up; TNTC, too numerous to count.
a Fisher’s test for significance between means.
b Associated with transformation means primary or Mets greater than nevi.
c Associated with progression means Mets greater than primary.
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Oncogenic Metastasis Drivers in Melanomathat: (1) ACP5 was the only gene exhibiting significant expres-
sion correlation with transformation aswell as progression (Table
1); and (2) Acp5 protein expression has been used as a histo-
chemical marker of osteoclastic activity, which is increased in
conditions of bone diseases including bone metastases (Halleen
et al., 2001; Capeller et al., 2003; Lyubimova et al., 2004).
To investigate ACP5’s ability to drive distal metastasis in vivo,
we overexpressed ACP5 or GFP control in the humanmelanoma
cell line 1205Lu, which shows minimal to no distal metastasis
from skin tumor sites. One million cells were then implanted
into a subcutaneous site in the skin on one flank of athymic
nude mice (n = 5) and followed for primary tumor growth. When
tumor size reached 2 cm in one dimension, the maximum size
allowed by our experimental protocol, animals were sacrificed
and examined for macrometastasis and micrometastasis in
lymph nodes and distal organ systems. Consistent with its inva-96 Cancer Cell 20, 92–103, July 12, 2011 ª2011 Elsevier Inc.sive activity, animals bearing ACP5-expressing melanomas in
the subcutaneous sites developed spontaneous metastasis
to the lung and lymph nodes (n = 2) (Figure 4A), whereas none
in the control cohort harbored any metastatic lesion despite
similar tumor penetrance in both cohorts (n = 5 each). Addition-
ally, based on the prognostic significance of these genes in
human breast cancers (see below), we also utilized NB008
(mTerc/, p53+/; mTerc), a well-characterized, nonmetastatic
cell line originating froma spontaneousmurinemammary adeno-
carcinoma (mTerc/, p53+/) engineered to reexpress mTerc.
Specifically, GFP-labeled NB008 cells stably expressing ACP5
or vector control were orthotopically implanted into the right
inguinal mammary fat pad of athymic nude mice. Macroscopic
GFP-positive lesions in the lungs were scored at necropsy
when primary mammary tumors reached 2 cm (Figure 4B).
As shown by Kaplan-Meier metastasis-free survival analysis,
Figure 3. Assessment of Oncogenic Activity by Proinvasion Genes
(A) 1205Lu melanoma cells expressing nontargeting control (shGFP; NT) or individual shRNA hairpins against ACP5 (shACP5-2 and -4) were assayed for effects
on anchorage-independent growth in soft agar. Immunoblot depicts Acp5 protein knockdown with indicated hairpins.
(B) Kaplan-Meier tumor-free survival analysis for xenograft assays in Ncr-Nude mice using nontumorigenic HMEL468 cells (1 3 106 cells/injection site) stably
expressing GFP or ACP5 (n = 10 each). p value calculated by log rank test.
(C) M619 melanoma cells expressing nontargeting control (GFP) or individual shRNA hairpins against the indicated candidates were assayed for effects on
anchorage-independent growth in soft agar as in (A). See Figure S4 for additional data using C918 melanoma cells and complementary knockdown verification
data.
(D) Kaplan-Meier tumor-free survival analysis for xenograft assays in Ncr-Nude mice using nontumorigenic HMEL468 cells stably expressing the indicated genes
as in (B). Log rank-calculated p values for individual candidates indicated at right of plot. Error bars indicate ± SD.
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(eight of nine) ofmice bearingACP5-expressing tumors, whereas
none (zeroof eight) of theanimals injectedwith control tumor cells
presented with lung nodules (p = 0.0003; Figure 4B). Histopatho-
logical examination confirmed presence of macrometastases
and micrometastases (Figure 4C). Together, these results show
that ACP5 is a bona fide metastasis driver in vivo.
Next, to investigate the prognostic significance of ACP5
expression in human primary melanomas, we again employed
the quantitative immunofluorescence measurement of Acp5
protein expression on a tissue microarray (YTMA59) containing
196 cases of primary melanomas and 299 cases of metastatic
melanomas annotated for survival outcome (Berger et al.,
2005; Gould Rothberg et al., 2009). As observed in the clinico-
pathological validation study (Figure S3), Acp5 staining was
primarily cytoplasmic, and the differential distributions of
staining intensity were significantly higher in the metastatic
lesions compared to primary specimens (Figure 5A) (ANOVA,
p < 0.0001). Importantly, the Acp5 protein level in primary
melanomas correlates with survival of patients, for which
a significantly shorter melanoma-specific survival was
observed in cases with higher cytoplasmic Acp5 levels (log
rank, p = 0.0258) (Figures 5B and 5C; Figure S5). Therefore,
collectively, our data show that ACP5 is not only a proinvasiononcogene but also a prognostic biomarker in human primary
melanomas.
On the cell biological level, overexpression and RNAi knock-
down of ACP5 resulted in striking morphological changes such
as cell spreading and cell rounding, respectively (Figure 6A),
prompting us to consider the possibility that ACP5 could modu-
late phosphorylation of focal adhesion complexes that are inte-
gral to cell attachment and motility. Indeed, overexpression of
ACP5 in melanoma cells led to a reproducible decrease in focal
adhesion kinase (FAK) autophosphorylation at Tyr397 (Figure 6B)
and global FAK tyrosine phosphorylation beyond its autophos-
phorylation site (Figure 6C). Similar analysis uncovered a more
significant effect of ACP5 overexpression on tyrosine phosphor-
ylation of Paxillin (PAX) (Figure 6C), including Tyr118 (Figure S6),
which is thought to serve as a critical docking site for other
signaling molecules. Live-cell imaging of ACP5 overexpressing
cells translated these biochemical changes to increased cell
movement (Movies S1 and S2), consistent with our data on
ACP5’s activity on cell invasion. Given the literature implicating
the FAK complex activity in metastasis (Zheng and Lu, 2009),
this mechanistic link thus further substantiates the functional
role of ACP5 in invasion and points to the FAK complex as
a possible point of therapeutic intervention in high-risk primary
melanoma with high ACP5 expression.Cancer Cell 20, 92–103, July 12, 2011 ª2011 Elsevier Inc. 97
Figure 4. In Vivo Metastasis Studies
(A) Representative H&E of lung and lymph nodemetastases in athymic mice (two of five) harboring subcutaneous tumors generated from 1205Lumelanoma cells
expressing ACP5. No metastases (zero of five animals) were detected in the GFP-expressing control cohort. Scale bar, 200 mm.
(B) Mammary fat pad metastasis assay using GFP-positive nonmetastatic murine breast adenocarcinoma cells (NB008; 2 3 104 cells/injection site) stably ex-
pressing vector control orACP5. Endpoint primary tumor size (top) and Kaplan-Meier metastasis-free survival analysis (bottom) are shown. p values calculated by
two-tailed Student’s t test (top) and log rank (bottom).
(C) Representative images of GFP-positive lung metastases and H&E sections of infiltrated lung from the ACP5 cohort. Arrows denote micrometastases. Scale
bars, 5.5 mm (left two panels) 300 mm (right four H&E panels).
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Although the majority of proinvasion genes identified from our
integrated functional genetic screen have not been linked to
metastasis (see Discussion), the actin-bundling protein Fscn1
is reported to be prognostic in numerous cancer types (Hashi-
moto et al., 2005), and recently shown to be required for metas-
tasis (Chen et al., 2010). This led us to explore the prognostic
relevance of these proinvasion genes in other tumor types using
RNA expression, given the limitation of antibody reagent for
quantitative protein-based assays. We focused specifically on
breast cancer based on the availability of three independent
cohorts of transcriptome data sets on stage I/II breast adenocar-
cinomas with outcome (recurrence or metastasis-free survival)
annotation (van de Vijver et al., 2002; Pawitan et al., 2005; Sotir-
iou et al., 2006). As summarized in Figure 7A, expression levels
of the 18 proinvasion genes were able to stratify patients by
K-means clustering into two subgroups with significant
differences in metastasis-free or recurrence-free survival by
Kaplan-Meier survival analysis in all 3 independent data sets.
Moreover, by C statistics these 18 genes were comparable to
the 70 genes in the FDA-approved MammaPrint in their ability98 Cancer Cell 20, 92–103, July 12, 2011 ª2011 Elsevier Inc.to prognosticate recurrence or metastasis (Figure 7B). These
data are remarkable in light of the fact that these genes were
discovered in melanoma. Such cross-tumor prognostic signifi-
cance reinforces the human relevance and highlights the power
of this integrative functional genomics approach for discovery
of metastasis oncogenes that can function across different
tumor types.
DISCUSSION
In this study we employed well-defined GEM models, compara-
tive oncogenomics, and functional genomics to identify genes
capable of driving invasion and transformation in early-staged
melanomas. The genomic and biological homogeneity of GEM
tumors and filtering power of cross-species comparisons proved
highly effective in generating a shorter, more biologically signifi-
cant list of genes enriched for cancer- and metastasis-relevant
networks than either human or mouse data sets alone. Subse-
quent functional screen and stringent validation efforts identified
high-priority drivers of invasion—the key biological process
that correlates with metastatic potential in melanoma. Finally,
Figure 5. Acp5 Expression on Melanoma
Tissue Microarrays
(A) Box plot demonstrating the distribution of
Acp5 cytoplasmic scores for primary (n = 182) and
metastatic (n = 325) lesions on the Yale Melanoma
Outcome Annotated TMA (YTMA59). p value
calculated by mixed-model ANOVA. Error bars
indicate data within 1.5 interquartile range of the
mean.
(B) Primary tumors from (A) were divided into
quartiles based on cytoplasmic expression of
Acp5. Comparison of melanoma-specific survival
of the lowest quartile (green) with the other three
quartiles (red) is shown. p value calculated by log
rank test.
(C) Representative staining of Acp5 (red) across
histospot tumor specimens on YTMA59. S100/
GP100 (green) defines tumor and nonnuclear
compartments, and DAPI (blue) defines the
nuclear compartments. Scale bars, 100 mm.
See also Figure S5.
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Oncogenic Metastasis Drivers in Melanomaalthough oncogenic activity was not screened for, it is remark-
able that every one of the six proinvasion genes is robustly trans-
forming in vivo, a finding that supports the hypothesis that
drivers of metastasis in early-staged primary tumors also serve
as professional oncogenes promoting tumorigenesis.
Of the six validated metastasis oncogenes, most are not
known or implicated in metastasis, although some have been
linked to cancer. For example, HSF1 (Heat Shock Factor 1) is
a regulator of cell transformation and in vivo tumorigenesis
(Dai et al., 2007), and HSF1-deficient cells exhibit markedly
impaired migration and MAP kinase signaling (O’Callaghan-
Sunol and Sherman, 2006). In a transgenic mouse model with
overexpression of NDC80, a component of the spindle check-
point, tumor development was reported in multiple organs
(Diaz-Rodriguez et al., 2008), and depletion of NDC80 impairs
tumor growth (Gurzov and Izquierdo, 2006). HOXA1 (Homeobox
Transcription factor 1) has oncogenic activity in mammary tumor
models (Zhang et al., 2003) and is upregulated in multiple human
cancers, including breast, squamous cell carcinoma, and mela-
noma (Chariot and Castronovo, 1996; Maeda et al., 2005; Abe
et al., 2006). VSIG4 (V-set and immunoglobulin domain contain-
ing 4) is a cell surface protein whose expression is mainly
restricted to macrophages where it functions as a potent T cell
inhibitor (Vogt et al., 2006; Xu et al., 2010). Based on its signifi-
cantly higher expression in aggressive breast and ovarian
tissues compared to benign tissues, ACP5 expression has
been suggested to represent a progression marker (Honig
et al., 2006; Adams et al., 2007), consistent with our data in
melanoma. Although we have shown in model systems that
ACP5 overexpression alone was sufficient in conferring distal
metastasis in vivo, frank metastasis in patients most certainly
requires cooperation of a multitude of genetic alterations, each
driving one or more steps in the metastatic cascade. Therefore,
one may speculate that there would be metastasis oncogenes
that are drivers of other biological processes (besides invasion)
that are required for metastasis; thus, a similar integrated
functional genomics approach could be powerful in aiding their
discovery.The majority of cancer-related deaths result from metas-
tases. With the improvement of early detection capability by
serum biomarkers and imaging advances, an increasing
number of cancer cases will be diagnosed and surgically re-
sected prior to apparent metastatic spread, leading to better
overall survival relative to high-stage disease. At the same
time, it is long recognized that equivalent low-stage cancers
are clinically heterogeneous with a subset exhibiting high-risk
behavior, recurring with metastatic spread in the years ahead.
The precise identification of such high-risk cases would enable
more aggressive management in adjuvant setting, while avoid-
ing unnecessary treatment in those patients cured by surgical
intervention alone. Therefore, there is a growing need for the
development of molecular-based prognostic biomarkers that
can stratify risk for metastasis in the early-stage cancer popu-
lation that constitutes an increasing proportion of cancer diag-
noses each year. Transcriptomic and genomic characterization
of human cancers supports the presence of molecular signals
resident in primary tumors that can predict risk for metastasis.
The development of MammaPrint and OncotypeDx has
provided a strong measure of clinical proof of this concept. In
comparison to the predominantly statistical correlative analyses
from which these signatures were derived, the approach
reported here focuses on discovery of functional drivers of
the metastatic process that are also oncogenic in early-stage
cancers. Given their functional nature, we believe that the
mechanism-of-action through which these proinvasion
oncogenes drive metastasis would inform evidence-based
therapeutic decisions in the adjuvant setting, in addition to
themselves being rational points for therapeutic intervention.
In this regard the convergence of emerging targeted therapeu-
tics for melanoma (such as the selective BRAF inhibitor)
and identification of proinvasion oncogenes as prognostic
biomarkers (such as ACP5) will offer a real opportunity to
stratify a molecularly high-risked subpopulation among patients
with early-stage primary melanoma for clinical investigation
aimed to explore the efficacy of these new therapies in the
prevention of recurrence and metastasis.Cancer Cell 20, 92–103, July 12, 2011 ª2011 Elsevier Inc. 99
Figure 6. ACP5 Expression Modulates Phosphorylation Status of Adhesion Molecules
(A) Morphology of WM115 (top) cells without (Vec) or with ACP5 overexpression, or 1205Lu cells (bottom) treated with a control shRNA (shNT) or an shRNA
targeting ACP5 (shACP5). Scale bars, 10 mm (top) and 5 mm (bottom).
(B) Immunoblot analysis of indicated proteins of WM115 cells expressing empty vector (EV) or ACP5 and grown on plates without coating or coated with Matrigel
or fibronectin as indicated.
(C) Protein lysates extracted fromWM115 and HMEL468 cells were immunoprecipitated (IP) with antibodies against FAK (or F) and PAX (or P) for immunoblotting
with the indicating antibodies. Tyrosine phosphorylation (pTyr) is determined by anti-pTyr immunoblot analysis.
See also Figure S6, and Movies S1 and S2.
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GEM Models for Melanoma, Comparative Data Analyses,
and In Vivo Tumor Assays
All mice were bred and maintained under defined conditions at the Dana-
Farber Cancer Institute (DFCI), and all procedures were approved by the
Animal Care andUseCommittee of DFCI and conformed to the legal mandates
and national guidelines for the care and maintenance of laboratory animals.
The tetracycline-inducible MET-driven mouse model (iMet) was constructed
similarly to the previously described iHRAS* model (Chin et al., 1999). Mice
were sacrificed according to institute guidelines, and organs were fixed in
10% buffered formalin and paraffin embedded. Tissue sections were stained
with H&E to enable classification of the lesions and detection of tumor metas-
tasis. For detection of Met protein, tumor sections were immunostained with
total Met and phospho Met (Tyr1349) antibodies (Cell Signaling Technology).
iMet tumors were additionally immunostained with S100 antibody (Sigma).
RNA from cutaneous melanomas derived from iMet or iHRAS* models was
profiled on Affymetrix Gene Chips, and resultant transcriptomes were
compared using Significance Analysis of Microarray (SAM 2.0) to generate
a phenotype-based (metastatic capable or not) differentially expressed gene
list. Cross-species triangulation to human gene expression and CNAs was
based on ortholog mapping. See Supplemental Experimental Procedures for
more details.
For xenograft tumorigenicity studies, HMEL468 cells were transduced
with pLenti6/V5 DEST-generated virus for stable expression of GFP (control)
or the indicated genes. Following selection with blasticidin (Invitrogen;
5 mg/ml) for 5–7 days, 1.0 3 106 cells (prepared in Hank’s balanced salts
[HBSs] at 1:1 with Matrigel) were injected subcutaneously into the right
flank of NCr-Nude (Taconic) mice. Two-tailed Student’s t test calculations
were performed using Prism 4 (GraphPad). In vivo metastasis assays
were performed by: (1) subcutaneous skin tumor assays using 1205Lu cells
stably expressing GFP (control) or ACP5; and (2) orthotopic mammary fat
pad assays using nonmetastatic NB008 adenocarcinoma cells stably
expressing vector (control) or ACP5, as described in Supplemental Experi-
mental Procedures.100 Cancer Cell 20, 92–103, July 12, 2011 ª2011 Elsevier Inc.Cell Culture
HMEL468 primed melanocytes were a subclone of PMEL/hTERT/
CDK4(R24C)/p53DD/BRAFV600E cells, as described (Garraway et al., 2005).
The nonmetastatic NB008 cell line was established from a spontaneous tumor
isolated from the breast of a G4 52-week-old female mTerc/, p53+/mouse.
GFP-mTerc was reintroduced into the resulting cell line by lentiviral transduc-
tion prior to use in these studies. TheWM115 melanoma cell line was obtained
from the Wistar Institute, and the 1205Lu melanoma cell line was obtained
from the American Type Culture Collection. M619 and C918 melanoma lines
have been described previously (Maniotis et al., 1999). All cell lines were prop-
agated at 37C and 5% CO2 in humidified atmosphere in RPMI 1640 medium
supplemented with 10% FBS.
Invasion Screen and Transwell Invasion Assays
The low-complexity genetic screen for cell invasion was performed using Tert-
immortalized melanocytes HMEL468 in 96-well modified Boyden chambers
coated with Matrigel (96-well tumor invasion plates; BD Bioscience) following
the manufacturer’s recommendations. Invaded cells were detected with
labeling using 4 mM Calcein AM (BD Bioscience) and measured by fluores-
cence at 494/517 nm (Abs/Em) after 20 hr incubation at 37C and 5% CO2.
Positive-scoring candidates were identified as those scoring 23 standard
deviations from the vector control. See Supplemental Experimental Proce-
dures for details on the screen and individual clones. Validation assays for
cell invasion were performed in standard 24-well invasion chambers contain-
ing Matrigel following the manufacturer’s recommendations. Following 20 hr
incubation at 37C and 5% CO2, chambers were fixed in 10% formalin and
stained with crystal violet for manual counting or by pixel quantitation with
Adobe Photoshop (Adobe). Data were normalized to input cells to control for
differences in cell number (loading control).
AQUA
Use of human tissues in this study is approved by the Yale institutional IRB,
HIC protocol number 9500008219 including consent and waived consent.
AQUA, Yale Melanoma Arrays, and tissue microarray construction have
been described previously (Camp et al., 2002; Gould Rothberg et al., 2009).
Figure 7. Kaplan-Meier Survival Curves in Breast Cancer Cohorts
(A) K-means clustering analysis based on the 18 gene proinvasion oncogene (top) and MammaPrint (bottom) signature using three independent cohorts of
early-staged breast cancers: NKI metastasis-free survival (MFS) (van de Vijver et al., 2002); NCI recurrence-free survival (RFS) (Sotiriou et al., 2006); and
Stockholm RFS (Pawitan et al., 2005). p values calculated by log rank test.
(B) Comparison of the 18-gene signature performance with the MammaPrint (Agendia, Huntington Beach, CA, USA) prognostic signature using the patient
cohorts specified in (A). HR, hazard ratio; C, C statistics.
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Oncogenic Metastasis Drivers in MelanomaArrays were stained with the following antibodies: monoclonal anti-Fscn1
diluted 1:500 (clone 55K2; Santa Cruz Biotechnology, Inc.); polyclonal anti-
Hoxa1 diluted 1:50 (BO1P; Abnova); polyclonal anti-Hsf1 diluted 1:2500
(AO1; Abnova); monoclonal anti-Ndc80 diluted 1:50 (clone 1A10; Abnova);
monoclonal anti-Acp5 diluted 1:100 (clone 26E5; Abcam); polyclonal anti-
Ncaph diluted 1:750 (Bethyl Laboratories, Inc.); and polyclonal anti-Vsig4
diluted 1:1000 (ab56037; Abcam). See Supplemental Experimental Proce-
dures for full details.Anchorage-Independent Growth Assays
Soft-agar colony formation assays were performed on 6-well plates in tripli-
cate for cells transduced with pLKO-shGFP (Open Biosystems) or shRNA
(Bill Hahn, DFCI/Broad Institute; available via Open Biosystems) hairpins
targeting the indicated genes (see Supplemental Experimental Procedures
for additional clone information). Cells were selected for 5 days with
2.5 mg/ml puromycin, and 1 3 104 cells were mixed thoroughly in cell growth
medium containing 0.4% SeaKem LE agarose (Fisher) in RPMI plus 10%
FBS, followed by plating onto bottom agarose prepared with 0.65% agarose
in RPMI plus 10% FBS. Each well was allowed to solidify and subsequently
covered in 1 ml RPMI plus 10% FBS plus P/S, which was refreshed every
4 days. Colonies were stained with 0.05% (wt/vol) iodonitrotetrazolium
chloride (Sigma) and scanned at 1200 dpi using a flatbed scanner, followed
by counting and two-tailed Student’s t test calculation using Prism 4 (Graph-
Pad). Verification of knockdown was achieved by qRT-PCR (described in
Supplemental Experimental Procedures) using gene-specific primer sets
(SABiosciences).Coimmunoprecipitation and Immunoblotting
For immunoprecipitation studies, lysates were prepared in NP-40 buffer
(20 mM Tris-HCl [pH 8.0], 150 mM NaCl, 2 mM EDTA, 1% NP-40) containing
1 mM PMSF, 13 Protease Inhibitor Cocktail (Roche), and 13 Phosphatase
inhibitor (Calbiochem) for immunoprecipitation. Anti-Paxillin (Abcam) or anti-
FAK (Santa Cruz Biotechnology) antibody was added to cell lysates for 2 hr
at 4Cwith rocking, followed by incubation overnight with protein G sepharose
(Roche) at 4C with rocking. Immunoprecipitates were washed three times for
10 min with lysis buffer, eluted by the addition of SDS loading buffer after
centrifugation, and resolved on NuPAGE 4%–12% Bis-Tris gels (Invitrogen)
for immunoblotting on PVDF (Millipore). The following antibodies were used
for immunoblotting following the manufacturer’s recommendations: anti-FAK
(Santa Cruz Biotechnology); anti-FAK (Tyr397; Cell Signaling); anti-Paxillin
(Abcam); anti-Paxillin (Tyr118; Cell Signaling); anti-Vinculin (Santa Cruz
Biotechnology); anti-V5 (for Acp5 detection; Invitrogen); and anti-phospho-
tyrosine (Millipore).Cell Imaging
Single-plane phase image was collected on a Nikon Ti with a 403 Plan-
Apochromatic phase objective NA 0.95 and a Clara camera using Andor iQ
software (Andor Technology). Time-lapse phase images were collected on
a Nikon TE2000-E with a 103 phase objective and an OrcaER camera (Hama-
matsu) at the DFCI Confocal and Light Microscopy Core. Shutters, stage posi-
tion, and camera were controlled by NIS-Elements software (Nikon, Melville,
NY). Images were collected every 2 min at 6–12 stage positions for 20 hr. A
representative time-lapse movie for vector and ACP5-overexpressing cellsCancer Cell 20, 92–103, July 12, 2011 ª2011 Elsevier Inc. 101
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Oncogenic Metastasis Drivers in Melanomaare shown. For the QuickTime movie, every tenth frame was used (20 min
time points) and playback is 15 frames per second.
Breast Cancer Prognostic Studies
Expression patterns of the 18 candidate preinvasion oncogenes and
MammaPrint 70-gene signature (Agendia, Huntington Beach, CA, USA)
were used for Kaplan-Meier survival analyses of the indicated breast cancer
data sets by K-means clustering using the survival package in R.
ACCESSION NUMBERS
Expression array data for the iMet and iHRAS* tumors generated by these
studies have been deposited into the GEO database with accession number
GSE29074.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, four tables, and twomovies and can be foundwith this article online
at doi:10.1016/j.ccr.2011.05.025.
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